Histone Deacetylase Inhibitors as Anticancer Drugs
Open accessThe DOI matches its Crossref record; 181 of the 184 references it cites were found in a registry or an index.
Abstract
Carcinogenesis cannot be explained only by genetic alterations, but also involves epigenetic processes. Modification of histones by acetylation plays a key role in epigenetic regulation of gene expression and is controlled by the balance between histone deacetylases (HDAC) and histone acetyltransferases (HAT). HDAC inhibitors induce cancer cell cycle arrest, differentiation and cell death, reduce angiogenesis and modulate immune response. Mechanisms of anticancer effects of HDAC inhibitors are not uniform; they may be different and depend on the cancer type, HDAC inhibitors, doses, etc. HDAC inhibitors seem to be promising anti-cancer drugs particularly in the combination with other anti-cancer drugs and/or radiotherapy. HDAC inhibitors vorinostat, romidepsin and belinostat have been approved for some T-cell lymphoma and panobinostat for multiple myeloma. Other HDAC inhibitors are in clinical trials for the treatment of hematological and solid malignancies. The results of such studies are promising but further larger studies are needed. Because of the reversibility of epigenetic changes during cancer development, the potency of epigenetic therapies seems to be of great importance. Here, we summarize the data on different classes of HDAC inhibitors, mechanisms of their actions and discuss novel results of preclinical and clinical studies, including the combination with other therapeutic modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“HDAC inhibitors have been considered for usage in combinatorial therapies for several cancers including melanoma47,65–67.”
From Epigenetic control of melanoma cell invasiveness by the stem cell factor SALL4 (2021) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“They work as anticancer drugs by inducing cell cycle arrest, differentiation, and cell death, and by reducing angiogenesis and modulating the immune response; however, the mechanisms of their effects can differ depending on the individual HDAC inhibitor and its dose and on the type of cancer [164].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [164]
In the citing paper
“HDAC inhibitors act as antitumoral agents by antagonizing the pro-transcriptional effects of histone deacetylation and silencing the expression of oncogenic factors through chromatin remodeling43.”
From Causal identification of single-cell experimental perturbation effects with CINEMA-OT (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R. I., Friedberg, J., Dent, P., & Grant, S. (2010) · Blood · doi:10.1182/blood-2009-12-257261 · Cited by 105 · cited 2×
“SAHA carfilzomib in vitro and nude mice xenografts, lymphoma cell SUDHL16, SUDHL4 , SUDHL6, OCI-LY10, OCI-LY3 bortezomib-resistant SUDHL16-10BR, OCI-LY10-40BR and lymphoma cells frompatients Potentiation [152]”
BackgroundRetractedDasmahapatra, G., Lembersky, D., Son, M. P., Attkisson, E., Dent, P., Fisher, R. I., Friedberg, J. W., & Grant, S. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1108 · Cited by 57 · cited 2×
“SNDX-275, SAHA carfilzomib, bortezomib in vitro and nude mice xenografts, lymphoma cell Granta 519, Rec-1, HF-4B, JVM-2, MINO, JVM-13 Potentiation [153]”
BackgroundRetractedBalliu, M., Guandalini, L., Romanelli, M. N., D’Amico, M., & Paoletti, F. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12345 · Cited by 31 · cited 3×
“Moreover, inhibition of HDAC6 activates naïve T cells [119,120].”
BackgroundRetractedThe Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325 · cited 1×
“The Wnt signaling pathway plays an important role in various cancers such as colon, breast, ovarian, prostate and endometrial cancers as well as medulloblastoma and melanoma [103].”
BackgroundMolecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 1×
“Several tumor associated antigens have been shown to be epigenetically silenced in malignancies impede immune recognition by cytotoxic T cells and contributing to worse prognosis [124,125].”
BackgroundActivation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
Dimmeler, S., Fleming, I., Fisslthaler, B., Hermann, C., Busse, R., & Zeiher, A. M. (1999) · Nature · doi:10.1038/21224 · Cited by 3,591
Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase
Brunet, A., Sweeney, L. B., Sturgill, J. F., Chua, K. F., Greer, P. L., Lin, Y., Tran, H., Ross, S. E., Mostoslavsky, R., Cohen, H. Y., et al. (2004) · Science · doi:10.1126/science.1094637 · Cited by 3,239 · cited 14×
“We found that VPA and TSA change CYP enzyme expression in neuroblastoma cells [135].”
BackgroundInfluentialCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203 · cited 2×
“Therefore, HDACs may be essential for the maintenance of a set of key genes required for survival and growth of cancer cells but not of normal ones [38].”
BackgroundAnticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 1×
“HATs catalyze the transfer of an acetyl group from acetyl-CoA to the ε-NH2 group of lysine residues in proteins, while HDACs remove it [12].”
BackgroundRegulation of endothelium-derived nitric oxide production by the protein kinase Akt
Fulton, D., Gratton, J.-P., McCabe, T. J., Fontana, J., Fujio, Y., Walsh, K., Franke, T. F., Papapetropoulos, A., & Sessa, W. C. (1999) · Nature · doi:10.1038/21218 · Cited by 2,608 · cited 1×
“eNOS, Akt in vitro endothelial cells, Akt transfected, mutatnteNOS / [110]”
Background
Cited by
Items 401–500 of 1,000
Discovery of 2,5-diphenyl-1,3,4-thiadiazole derivatives as HDAC inhibitors with DNA binding affinity
Chen, C., Chu, H., Wang, A., Yin, H., Gao, Y., Liu, S., Li, W., & Han, L. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114634 · Cited by 26
Bound, N. T., Vandenberg, C. J., Kartikasari, A. E. R., Plebanski, M., & Scott, C. L. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.886170 · Cited by 34
HDAC inhibitors: Promising agents for leukemia treatment
Deng, Y., Qian, C., & He, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.09.023 · Cited by 26
Chao, S.-W., Chen, L., Yu, C.-C., Liu, C., Lin, T. E., Guh, J., Wang, C.-Y., Chen, C.-Y., Hsu, K., & Huang, W. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.11.092 · Cited by 26
Epigenetic‐based therapy for colorectal cancer: Prospect and involved mechanisms
Rezapour, S., Hosseinzadeh, E., Marofi, F., & Hassanzadeh, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28658 · Cited by 27
Chung, L.-Y., Tang, S., Wu, Y., Yang, K., Huang, H., Sun, G., & Sun, K. (2019) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14898 · Cited by 28
Shen, L., Jin, X., Wang, X., Tou, L., & Huang, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000745 · Cited by 27
“Histone acetylation makes chromatin more relaxed and facilitates gene transcription while deacetylation induces chromatin condensation and represses gene transcription.([102]) With the great impact on epigenetic, aberrant activity of HDACs has been demonstrated in breast cancer.”
BackgroundHamoud, M. M. S., Pulya, S., Osman, N. A., Bobde, Y., Hassan, A. E. A., Abdel‐Fattah, H. A., Ghosh, B., & Ghanim, A. M. (2020) · New Journal of Chemistry · doi:10.1039/d0nj01274b · Cited by 25
The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2018.1437156 · Cited by 24
The histone deacetylase inhibitor entinostat/syndax 275 in osteosarcoma
Kiany, S., Harrison, D., & Gordon, N. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-43032-0_7 · Cited by 24
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability
Garcha, H. K., Olaoye, O. O., Sedighi, A., Pölöske, D., Hariri, P., Yu, W., Abdallah, D. I., Moriggl, R., de Araujo, E. D., & Gunning, P. T. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02021 · Cited by 24
Epigenetic Changes as a Target in Aging Haematopoietic Stem Cells and Age-Related Malignancies
Buisman, S. C., & de Haan, G. (2019) · Cells · doi:10.3390/cells8080868 · Cited by 27
Trifluoromethyloxadiazoles: inhibitors of histone deacetylases for control of Asian soybean rust
Winter, C., Fehr, M., Craig, I. R., Grammenos, W., Wiebe, C., Terteryan‐Seiser, V., Rudolf, G. C., Mentzel, T., & Palomar, M. A. Q. (2020) · Pest Management Science · doi:10.1002/ps.5874 · Cited by 25
HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights
Passaro, E., Papulino, C., Chianese, U., Toraldo, A., Congi, R., Gaudio, N. D., Nicoletti, M. M., Benedetti, R., & Altucci, L. (2021) · Cancers · doi:10.3390/cancers13246280 · Cited by 26
“HDACi are therefore considered promising anticancer drugs, especially since they can be used in combination with chemotherapeutics and/or radiotherapy [41].”
BackgroundZhu, F., Meng, X., Liang, H., Sheng, C., Dong, G., Liu, D., & Wu, S. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105702 · Cited by 24
The role of miR-155 on liver diseases by modulating immunity, inflammation and tumorigenesis
Xue, X., Wang, J., Fu, K., Dai, S., Wu, R. T., Peng, C., & Li, Y. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109775 · Cited by 28
Role of Histone Deacetylase 6 and Histone Deacetylase 6 Inhibition in Colorectal Cancer
Vuletić, A. M., Martinović, K. M., & Spasić, J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010054 · Cited by 24
“In this sense, suberoylanilide hydroxamic acid (SAHA, vorinostat) was the first approved pan-HDACi by the FDA, initially for the treatment of relapsed and refractory cutaneous T-cell lymphoma [158–160].”
BackgroundBalestrieri, E., Argaw-Denboba, A., Gambacurta, A., Cipriani, C., Bei, R., Serafino, A., Vallebona, P. S., & Matteucci, C. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01448 · Cited by 24
Fox, C. R., & Parks, G. D. (2019) · Viruses · doi:10.3390/v11050431 · Cited by 26
“Importantly however, many HDAC inhibitors have been shown to have little cytotoxic effect on normal cells [29].”
BackgroundSohaib, M., & Ezhilarasan, D. (2019) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-019-00286-x · Cited by 24
ElHady, A. K., Shih, S., Chen, Y.-C., Liu, Y., Ahmed, N. S., Keeton, A. B., Piazza, G. A., Engel, M., Abadi, A., & Abdel‐Halim, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103742 · Cited by 24
Rausch, M., Weiss, A., Zoetemelk, M., Piersma, S. R., Jiménez, C. R., van Beijnum, J. R., & Nowak-Sliwinska, P. M. (2020) · Cancers · doi:10.3390/cancers12113172 · Cited by 25
“Drugs targeting these aberrant epigenetic processes have emerged as an e ff ective therapeutic strategy and therefore, histone deacetylase inhibitors (HDACIs) nowadays play an important role in combating cancer [2].”
He, L., Wen, S., Zhong, Z., Weng, S., Jiang, Q., Mi, H., & Liu, F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625543 · Cited by 28
“Through the Therapeutic Target database (TTD), we finally identified that SAHA, a histone deacetylase (HDAC) inhibitor (Eckschlager et al., 2017), can work synergistically with 5-ASA.”
BackgroundFeng, Y., Lu, Y., Li, J., Zhang, H., Li, Z., Feng, H., Deng, X., Liu, D., Shi, T., Jiang, W., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113888 · Cited by 25
HDAC8 as a target in drug discovery: Function, structure and design
Zhao, Q., Liu, H., Peng, J., Niu, H., Liu, J., Xue, H., Liu, W., Liu, X., Hao, H., Zhang, X., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116972 · Cited by 25
Sixto‐López, Y., Rosales‐Hernández, M. C., de Oca, A. C.-M., Morales, L. G. F., Mendieta‐Wejebe, J. E., Correa-Basurto, A. M., Abarca‐Rojano, E., & Correa‐Basurto, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165873 · Cited by 23
“In this sense, some studies have explored histone deacetylases inhibitors (HDACi) for the treatment of cancers due to its cytotoxic effects inducing cell cycle arrest and apoptosis, among other anticancer effects [5,6].”
BackgroundLanzi, C., Favini, E., Bo, L. D., Tortoreto, M., Arrighetti, N., Zaffaroni, N., & Cassinelli, G. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02150-y · Cited by 26
“ERK signaling overactivation plays a key role in counteracting cell response to HDACi and synergistic inhibitory effects between HDACi and agents targeting the ERK pathway have been demonstrated in both hematological and solid tumor models [12, 63, 66, 100, 101].”
BackgroundInfluentialTsai, Y.-C., Chen, H., Lee, T.-H., Chang, H.-M., Wu, K., Chuang, C., Chang, Y.-C., Tu, Y., Hung, J., Yang, C., et al. (2021) · Cancers · doi:10.3390/cancers14010182 · Cited by 25
“The modification of histones through acetylation is controlled by the balance between HDACs and histone acetyltransferases [32].”
BackgroundRozman, M., Lepej, S. Ž., Jambrosic, K., Babić, M., & Hofman, I. D. (2023) · Pathogens · doi:10.3390/pathogens12010092 · Cited by 25
“Therefore, their inhibitors, such as valproic acid, vorinostat, and givinostat, are used as LRAs to activate the latent HIV-1 reservoir [86].”
Wahi, A., Jain, P., Sinhari, A., & Jadhav, H. R. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02674-4 · Cited by 25
A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors
Drakontaeidi, A., & Pontiki, E. A. (2023) · Pharmaceuticals · doi:10.3390/ph16121639 · Cited by 30
“Aberrant histone acetylation, resulting in disrupted transcription, is now acknowledged as a hallmark of numerous types of cancer [7,18–20].”
BackgroundSpecific vaginal and gut microbiome and the anti-tumor effect of butyrate in cervical cancer women
Han, M., Wang, N., Han, W., Liu, X., Sun, T., & Xu, J. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.101902 · Cited by 26
“It has been shown that the anticancer effect of butyric is attributed to its function as an inhibitor of histone deacetylase (HDAC) [40].”
BackgroundLuparello, C., Asaro, D. M. L., Cruciata, I., Hassell‐Hart, S., Sansook, S., Spencer, J., & Caradonna, F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040804 · Cited by 24
“Food and Drug Administration, a great number of them are undergoing clinical trials in order to thoroughly exploit their full potential as anticancer agents [3,4].”
Epigenetics in dilated cardiomyopathy
Yu, J., Zeng, C., & Wang, Y. (2019) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000616 · Cited by 24
Do Global Regulators Hold the Key to Production of Bacterial Secondary Metabolites?
Thapa, S. S., & Grove, A. (2019) · Antibiotics · doi:10.3390/antibiotics8040160 · Cited by 28
“Thus, HDAC inhibitors prevent deacetylation, leading to an accumulation of hyperacetylated nucleosomes and differential gene expression [49].”
BackgroundYoshikawa, Y., Kuribayashi, K., Minami, T., Ohmuraya, M., & Kijima, T. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554570 · Cited by 25
Ullmann, T., Luckhardt, S., Wolf, M., Parnham, M. J., & Resch, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063022 · Cited by 25
Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics
Taiarol, L., Bigogno, C., Sesana, S., Kravicz, M., Viale, F., Pozzi, E., Monza, L., Carozzi, V., Meregalli, C., Valtorta, S., et al. (2022) · Cancers · doi:10.3390/cancers14122978 · Cited by 25
“This theme has inspired researchers to develop different classes of HDAC inhibitors (HDACis), some of which are in clinical trials for the treatment of tumors [5,6].”
BackgroundSehgal, M., Jakhete, S. M., Manekar, A. G., & Sasikumar, S. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09773 · Cited by 24
“been approved for treating various diseases like cancer [273, 275].”
Sun, S., Zhao, W., Li, Y., Chi, Z., Fang, X., Wang, Q., Han, Z., & Luan, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104652 · Cited by 22
Synthesis of HDAC Inhibitor Libraries via Microscale Workflow
Dykstra, K. D., Streckfuss, E. C., Liu, M., Liu, J., Yu, Y., Wang, M., Kozlowski, J. A., Myers, R. W., Buevich, A. V., Maletic, M. M., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.0c00596 · Cited by 22
Streubel, G., Schrepfer, S., Kallus, H., Parnitzke, U., Wulff, T., Hermann, F., Borgmann, M., & Hamm, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88983-1 · Cited by 25
Mehrpouri, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108114 · Cited by 25
Exploring Therapeutic Avenues in Lung Cancer: The Epigenetic Perspective
Munteanu, R. A., Tomuleasa, C., Iuga, C. A., Gulei, D., & Ciuleanu, T. (2023) · Cancers · doi:10.3390/cancers15225394 · Cited by 25
“HDACi disrupts cancer cell processes such as cell proliferation, angiogenesis, differentiation, and apoptosis, causing cell cytotoxicity by influencing the expression of multiple genes and proteins [75].”
BackgroundClinical impact of epithelial–mesenchymal transition for cancer therapy
Mukerjee, N., Nag, S., Bhattacharya, B., Alexiou, A. T., Mirgh, D., Mukherjee, D., Adhikari, M. D., Anand, K., Muthusamy, R., Gorai, S., et al. (2024) · Clinical and Translational Discovery · doi:10.1002/ctd2.260 · Cited by 30
Uba, A. İ., & Yelekçi, K. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.05.004 · Cited by 22
Das, F., Maity, S., Ghosh‐Choudhury, N., Kasinath, B. S., & Choudhury, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.007023 · Cited by 22
“HDAC inhibitors have been tested clinically for various malignancies (56).”
BackgroundEpigenetic regulation of anterior segment diseases and potential therapeutics
Chen, E., Bohm, K. J., Rosenblatt, M., & Kang, K. B. (2020) · The Ocular Surface · doi:10.1016/j.jtos.2020.04.001 · Cited by 23
MLLT10 rearranged acute leukemia: Incidence, prognosis, and possible therapeutic strategies
Forgione, M. O., McClure, B. J., Yeung, D. T. O., Eadie, L. N., & White, D. L. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22887 · Cited by 27
“(Table 1 and Figure 1).2 Despite historically poor outcomes compared with B-ALL, intensification of modern che- motherapy protocols has improved long-term overall survival of T- ALL to 80% in children and 60% in adults, comparable with B-ALL outcomes.20,21 However, outcomes after relapse or treatment failure remain po…”
BackgroundInfluentialShirbhate, E., Patel, P., Patel, V. K., Veerasamy, R., Sharma, P. C., & Rajak, H. (2020) · Future Oncology · doi:10.2217/fon-2020-0385 · Cited by 25
Molecular Fingerprints of Malignant Pleural Mesothelioma: Not Just a Matter of Genetic Alterations
Lorenzini, E., Ciarrocchi, A., & Torricelli, F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10112470 · Cited by 24
“Lysine acetylation and deacetylation are catalyzed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively [73,74].”
BackgroundKhusnutdinova, E. F., Petrova, A. V., Zileeva, Z. R., Kuzmina, U. S., Зайнуллина, Л. Ф., Vakhitova, Y. V., Babkov, D. A., & Kazakova, O. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22189796 · Cited by 25
“HDAC inhibitors mostly act via epigenetic regulation and are known to cause cell cycle arrest and apoptosis, reduce angiogenesis, and modulate immune response [57].”
BackgroundEpigenetic Modifications: Novel Therapeutic Approach for Thyroid Cancer
Zhu, X., & Cheng, S.-Y. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.3.326 · Cited by 22
Bastaki, K., Alwan, S. S., & Zahir, F. (2020) · Advances in neurobiology · doi:10.1007/978-3-030-30402-7_5 · Cited by 28
Epigenetic Effects of Blackberry Extract on Human Colorectal Cancer Cells
Tatar, M., Varedi, M., & Naghibalhossaini, F. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1952454 · Cited by 22
“The accumulated evidence suggests that HDACis can be used as anticancer therapeutics by inducing tumor cell death or differentiation (17,18).”
BackgroundTantawy, A. H., Meng, X., Marzouk, A. A. E., Fouad, A., Abdelazeem, A. H., Youssif, B. G. M., Jiang, H. X., & Wang, M. (2021) · RSC Advances · doi:10.1039/d1ra04061h · Cited by 21
Evidence that HDAC7 acts as an epigenetic “reader” of AR acetylation through NCoR-HDAC3 dissociation
Zhang, Y., Andrade, R. E., Hanna, A. A., & Pflum, M. K. H. (2022) · Cell chemical biology · doi:10.1016/j.chembiol.2022.05.008 · Cited by 23
Deng, J., Hou, B., Hou, X., Chen, Y., Zhang, T., Chen, H., Wang, Y., & Li, X. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115915 · Cited by 21
Černá, T., Hraběta, J., Eckschlager, T., Frei, E., Schmeiser, H. H., Arlt, V. M., & Stiborová, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010164 · Cited by 21
“Several mechanisms might be relevant for the biological activity of VPA: (i) it increases the DNA binding of activating protein-1 (AP-1) transcription factor and the expression of genes regulated by the extracellular-regulated kinase (ERK)-AP-1 pathway, (ii) VPA down-regulates protein kinase C (PKC) activity, (iii) in…”
BackgroundResultInfluentialSelf-citationYoon, G.-E., Jung, J. K., Lee, Y., Jang, B., & Kim, J. I. (2019) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-019-01749-5 · Cited by 23
“HDAC inhibitors have been studied primarily in the field of cancer and recently studied in cardiovascular diseases (Yoon and Eom 2016; Eckschlager et al. 2017).”
Zwergel, C., Bello, E. D., Fioravanti, R., Conte, M., Nebbioso, A., Mazzone, R., Brosch, G., Mercurio, C., Varasi, M., Altucci, L., et al. (2020) · ChemMedChem · doi:10.1002/cmdc.202000854 · Cited by 24
Design of Selective Histone Deacetylase Inhibitors: Rethinking Classical Pharmacophore
Melesina, J., Praetorius, L., Simoben, C. V., Robaa, D., & Sippl, W. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0125 · Cited by 22
HDAC Inhibitors recapitulate Human Disease-Associated Microglia Signatures in vitro
Haage, V. C., Tuddenham, J. F., Bautista, A. R., Garcia, F. G., White, C. C., Patel, R., Comandante-Lou, N., Marshe, V. S., Griffin, J. K., Zhou, Y., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.05.027 · Cited by 24
Sadia, K., Castagna, A., Udali, S., Ambrosani, F., Pattini, P., Beri, R., Argentino, G., Masutti, M., Moruzzi, S., & Friso, S. (2025) · Cells · doi:10.3390/cells14171337 · Cited by 22
“These inhibitors function through multiple mechanisms including immunomodulation, apoptosis induction and cell cycle arrest with current clinical trials testing both monotherapy and combination approaches with standard chemotherapy, immunotherapy and targeted agents [116,117].”
Friedrich, A., Aßmann, A.-S., Schumacher, L., van Stuijvenberg, J., Kassack, M. U., Schulz, W. A., Roos, W. P., Hansen, F. K., Pflieger, M., Kurz, T., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134747 · Cited by 23
“Taken together, both published in vitro and in vivo data, together with our results, imply that the promotion of genetic instability by currently available HDACi might be a class I/II-related effect resulting from on-target effects of these HDACi, which eventually influence DNA repair and DDR. Speculating that genetic…”
BackgroundInfluentialBieszczad, B., Garbicz, D., Świtalska, M., Dudek, M. K., Warszycki, D., Wietrzyk, J., Grzesiuk, E., & Mieczkowski, A. (2021) · Pharmaceuticals · doi:10.3390/ph14090851 · Cited by 21
Barciszewska, A., Belter, A., Gawrońska, I., Giel-Pietraszuk, M., & Naskręt-Barciszewska, M. Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1033035 · Cited by 20
“Frontiers in Oncology 10 target DNA sequence (39).”
BackgroundStransky, S., Cutler, R. R., Aguilan, J. T., Nieves, E., & Sidoli, S. (2022) · Epigenetics & Chromatin · doi:10.1186/s13072-022-00470-7 · Cited by 22
“HDACi can also have anti-cancer effects, which depend on the type of cancer and the treatment dose [22].”
BackgroundBello, E. D., Sian, V., Bontempi, G., Zwergel, C., Fioravanti, R., Noce, B., Castiello, C., Tomassi, S., Corinti, D., Passeri, D., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115022 · Cited by 20
Li, D., Zhang, Z., Li, Y., Wang, X., Zhong, H., Yang, H., Xi, Y., Liu, H., Shen, A., & Hu, Y. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00525 · Cited by 20
Epigenetic and Genetic Keys to Fight HPV-Related Cancers
Folliero, V., Dell’Annunziata, F., Chianese, A., Morone, M. V., Mensitieri, F., Spirito, F. D., Mollo, A., Amato, M., Galdiero, M., Piaz, F. D., et al. (2023) · Cancers · doi:10.3390/cancers15235583 · Cited by 24
Ye, L., Li, W., Tang, X., Xu, T. S., & Wang, G. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240128002056 · Cited by 22
“The precise mechanisms through which these compounds may operate are not completely clear, but epigenetic pathways are suggested [64].”
BackgroundSplicing modulator FR901464 is a potential agent for colorectal cancer in combination therapy
Yamano, T., Kubo, S., Yano, A., Kominato, T., Tanaka, S., Ikeda, M., & Tomita, N. (2019) · Oncotarget · doi:10.18632/oncotarget.26564 · Cited by 20
“FR901228 and other HDACIs with different chemical structures have similar biological effects on cancer cells, including induction of cell cycle arrest, differentiation, and apoptosis, by influencing transcriptional activity [6, 7].”
BackgroundBuckwalter, J. M., Chan, W. H.-C., Shuman, L., Wildermuth, T., Ellis-Mohl, J., Walter, V., Warrick, J. I., Wu, X., Kaag, M. G., Raman, J. D., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102599 · Cited by 20
“The clinical benefit of HDAC inhibitors (HDACi) on patient outcome has been limited and some clinical trials resulted in severe toxicities in patients [47].”
BackgroundYang, L., Qiu, Q., Tang, M., Wang, F., Yi, Y., Yi, D., Yang, Z., Zhu, Z., Zheng, S., Yang, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0516 · Cited by 21
“Except for chidamide as a class I HDAC- andHDAC10 subtype–selective inhibitor, romidepsin as a HDAC1- and HDAC2-selective inhibitor (33), the other three are pan-HDAC inhibitors (23).”
BackgroundSynthesis of certain benzothieno[3,2-d]pyrimidine derivatives as a selective SIRT2 inhibitors
Khalil, N. A., Ahmed, E., Zaher, A. F., El‐Zoghbi, M. S., & Sobh, E. A. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111926 · Cited by 20
ErbB2 Targeted Epigenetic Modulation: Anti-tumor Efficacy of the ADC Trastuzumab-HDACi ST8176AA1
Milazzo, F. M., Vesci, L., Anastasi, A. M., Chiapparino, C., Rosi, A., Giannini, G., Taddei, M., Cini, E., Faltoni, V., Petricci, E., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01534 · Cited by 22
“Moreover, since trastuzumab is currently being employed in clinical protocols for the treatment of pancreatic ductal adenocarcinoma in combination with chemotherapy (24) or with an HDACi (25), the anti-tumor activity of ST8176AA1 was investigated in two patient-derived xenograft (PDX)”
BackgroundWu, W.-C., Liu, Y.-M., Lin, M.-H., Liao, Y.-H., Lai, M.-J., Chuang, H., Hung, T.-Y., Chen, C., & Liou, J. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112158 · Cited by 20
Anti-VEGF Drugs Influence Epigenetic Regulation and AMD-Specific Molecular Markers in ARPE-19 Cells
Hamid, M. A., Moustafa, M. T., Nashine, S., Costa, R. D., Schneider, K., Atilano, S. R., Kuppermann, B. D., & Kenney, M. C. (2021) · Cells · doi:10.3390/cells10040878 · Cited by 21
“This could explain the fact that gene expression is not always silenced by deacetylation [27].”
BackgroundLi, Y., Quan, J., Song, H., Li, D., Ma, E., Wang, Y., & Ma, C. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105081 · Cited by 20
Kilgour, J. M., Shah, A. M., Urman, N. M., Eichstadt, S. L., Do, H., Bailey, I., Mirza, A., Li, S., Oro, A. E., Aasi, S. Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0560 · Cited by 26
“Ourfindings suggest that remetinostat is able to penetrate into the epidermis of skin and alter histone phosphorylation within 30 minutes of application in comparison with baseline, supporting the proposed mechanism of action by which HDAC inhibitors alter transcription of genes involved in cellular growth and prolife…”
Ronconi, L., Fotopoulou, E., & Titilas, I. (2021) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892816666210907101146 · Cited by 23
Lu, X., Jin, P., Tang, Q., Zhou, M., Xu, H., Su, C., Wang, L., Xu, F., Zhao, M., Yin, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202412109 · Cited by 32
Upadhyay, N., Tilekar, K. N., Safuan, S., Kumar, A. P., Schweipert, M., Meyer‐Almes, F., & Ramaa, C. S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105350 · Cited by 20
Shimada, H., Kohno, T., Konno, T., Okada, T., Saito, K., Shindo, Y., Kikuchi, S., Tsujiwaki, M., Ogawa, M., Matsuura, M., et al. (2021) · Cancers · doi:10.3390/cancers13246341 · Cited by 21
“According to recent studies, overexpression of HDACs is observed in various cancers [98].”
BackgroundInfluentialBiological function and small molecule inhibitors of histone deacetylase 11
Jia, G., Liu, J., Hou, X., Jiang, Y., & Li, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116634 · Cited by 20
Liang, R., Ding, D., Li, Y., Lan, T., Ryabtseva, S., Huang, S., Ren, J., Huang, H., & Wei, B. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02936-0 · Cited by 26
Pharmacoepigenetics and Pharmacoepigenomics: An Overview
Peedicayil, J. (2018) · Current Drug Discovery Technologies · doi:10.2174/1570163815666180419154633 · Cited by 21
Zhong, L., Zhou, S. W., Tong, R., Shi, J., Bai, L., Zhu, Y., Duan, X., Liu, W., Bao, J., Su, L., et al. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0651-4 · Cited by 19
IDH1R132H Causes Resistance to HDAC Inhibitors by Increasing NANOG in Glioblastoma Cells
Kim, G., Choi, S. Y., Oh, T.-I., Kan, S.-Y., Kang, H., Lee, S., Oh, T., Ko, H. M., & Lim, J.-H. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112679 · Cited by 21
“It is becoming clear that histone deacetylase inhibitors (HDACi), such as trichostatin A (TSA), SAHA (also known vorinostat), and valproic acid, are promising anti-cancer drugs in multiple types of cancer [35].”
BackgroundRecent Prospectives of Anticancer Histone Deacetylase Inhibitors
Abbass, S. A., Hassan, H. A., Mohamed, M. F. A., Moustafa, G. A. I., & Abuo‐Rahma, G. E. A. (2019) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2019.14468.1051 · Cited by 24
Kaur, N., Fang, Y.-C., Lee, H., Singh, A., Nepali, K., Lin, M.-H., Yeh, T., Lai, M.-J., Chan, L., Tu, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111915 · Cited by 19
Organoferroelastic Crystal Prepared by Supramolecular Synthesis
Sasaki, T., Sakamoto, S., & Takamizawa, S. (2020) · Crystal Growth & Design · doi:10.1021/acs.cgd.9b01606 · Cited by 19
Cancer stem cell antigens as targets for new combined anti-cancer therapies
Quaglino, E., Cavallo, F., & Conti, L. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105861 · Cited by 20
“Histone deacetylases and DNA methyltransferase (DNMT) inhibitors are currently used in clinical trials as they hinder tumor-cell growth and induce cell differentiation (73).”
Tavares, M. T., de Almeida, L. C., Kronenberger, T., Ferreira, G. M., de Divitiis, T. F., Toledo, M. F. Z. J., Hassimotto, N. M. A., Machado‐Neto, J. A., Costa-Lotufo, L. V., & Parise‐Filho, R. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116085 · Cited by 21
A fungal sirtuin modulates development and virulence in the insect pathogen, Beauveria bassiana
Cai, Q., Li, T., Xiè, J., Huang, Q., Feng, M., & Keyhani, N. O. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15497 · Cited by 21
Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies
Horowitz, N. B., Mohammad, I., Moreno‐Nieves, U. Y., Koliesnik, I. O., Tran, Q., & Sunwoo, J. B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.648580 · Cited by 20
Huê, B. T. B., Nguyen, P. H., Quân, P. M., Tran, H. P., Tran, Q. D., Jung, H., Hong, Q. V., Nguyễn, C. Q., Nguyen, Q. P., Le, H. T., et al. (2022) · Molecules · doi:10.3390/molecules27072204 · Cited by 19
“Among HDACIs, hydroxamate-based organic molecules are the most potent due to their strong metal ion binding property [7].”
BackgroundPai, P., Kumar, A., Shetty, M. G., Kini, S. G., Bhat, M. K., Satyamoorthy, K., & Babitha, K. S. (2022) · Journal of Molecular Modeling · doi:10.1007/s00894-022-05103-0 · Cited by 18
“Some of the HDAC class-specific inhibitors reported are nanatinostat (class I) and rocilinostat (class II) [6].”
BackgroundSun, L., Gao, L., Zhao, Y., Wang, Y., Xu, Q., Zheng, Y., Chen, J., He, W., & Wang, L. (2022) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892818666221201145810 · Cited by 19
Metadata
- Authors
- Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J.
- Affiliations
- Department of Pediatric Hematology and Oncology, 2nd Faculty of Medicine, Charles University and University Hospital Motol, V Uvalu 84/1, Prague 5 CZ-150 06, Czech Republic
- Charles University (CZ)
- Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030/8, Prague 2 CZ-128 43, Czech Republic
- ORCID
- Stiborova, Marie
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-07-01
- Volume
- 18
- Issue
- 7
- Pages
- 1414
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5535906
- OpenAlex
- W2724336500
- Cited by
- 1,206
- References
- 184
- Citations by year
- 2026: 64 · 2025: 107 · 2024: 107 · 2023: 140 · 2022: 164 · 2021: 195 · 2020: 170 · 2019: 164 · 2018: 85 · 2017: 9
- FWCI
- 11.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministerstvo Zdravotnictví Ceské Republiky (00064203)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, epigenetic regulation, histone acetylation, histone acetyltransferase, differentiation therapy, angiogenesis, immune response, vorinostat, romidepsin, belinostat, panobinostat, T-cell lymphoma, multiple myeloma, epigenetic therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Autophagy, Clinical Trials as Topic, Drug Evaluation, Preclinical, Humans, Signal Transduction, Gene Expression Regulation, Neoplastic, Apoptosis, Angiogenesis Inhibitors, Epigenesis, Genetic, Histone Deacetylase Inhibitors, Immunomodulation, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
